We will relentlessly pursue precision treatments for rare diseases with our novel therapeutics to enable people to live their absolute best lives.

Without Limits.

Announcement: Register to take part in our very first “Ask Thryv Live” webinar taking place on Tuesday, May 7th from 12:00 p.m. to 1:00 p.m. ET. Read More.

Our Focus:

Thryv Therapeutics is pioneering a precision medicine approach to treat indications including Congenital Long QT Syndrome (LQTS), atrial fibrillation and heart failure with potent and selective inhibitors of Serum Glucocorticoid inducible Kinase (SGK1).

Breaking Barriers:

Press Releases
Thryv Therapeutics to Participate at the Piper Sandler Spring Biopharma Symposium
Thryv Therapeutics to Participate at the Piper Sandler Spring Biopharma Symposium
Thryv Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Thryv Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Thryv Therapeutics to Present Results of Wave I Part 1 Clinical Study at American College of Cardiology Conference in Atlanta, Georgia on April 7th, 2024
Thryv Therapeutics to Present Results of Wave I Part 1 Clinical Study at American College of Cardiology Conference in Atlanta, Georgia on April 7th, 2024
Thryv Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference
Thryv Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference
2023 Year End Report
2023 Year End Report
Thryv Therapeutics to Present at the 2023 RBC Capital Markets Private Company Conference
Thryv Therapeutics to Present at the 2023 RBC Capital Markets Private Company Conference
Thryv Therapeutics’ CEO, Paul Truex, to Present at Piper Sandler’s 35th Annual Healthcare Conference
Thryv Therapeutics’ CEO, Paul Truex, to Present at Piper Sandler’s 35th Annual Healthcare Conference
Thryv Therapeutics Presents Benefits of Therapeutic SGK1 Inhibition with THRV-1268 in a Murine Model of Atrial Fibrillation at American Heart Association Scientific Sessions
Thryv Therapeutics Presents Benefits of Therapeutic SGK1 Inhibition with THRV-1268 in a Murine Model of Atrial Fibrillation at American Heart Association Scientific Sessions
Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study. LQT-1213 Rapidly and Meaningfully Reduces QT Interval in Individuals with Prolonged QT Induced by Dofetilide.
Thryv Therapeutics Announces Positive Results from the WAVE 1 Proof of Concept Study. LQT-1213 Rapidly and Meaningfully Reduces QT Interval in Individuals with Prolonged QT Induced by Dofetilide.
Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.
Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.
Thryv Therapeutics Announces Significant Progress Across all Programs within its SGK1 Inhibitor Portfolio and the Closing of a Convertible Note Financing with Investissement Québec
Thryv Therapeutics Announces Significant Progress Across all Programs within its SGK1 Inhibitor Portfolio and the Closing of a Convertible Note Financing with Investissement Québec
Thryv Therapeutics Inc. Announces Completion of Initial Phase 1 Clinical Study and Beginning of Proof of Efficacy Study in Long QT Syndrome
Thryv Therapeutics Inc. Announces Completion of Initial Phase 1 Clinical Study and Beginning of Proof of Efficacy Study in Long QT Syndrome
Pharmaceutical Commercialization Expert Melissa Koomey, M.B.A., Appointed to Thryv’s Board of Directors
Pharmaceutical Commercialization Expert Melissa Koomey, M.B.A., Appointed to Thryv’s Board of Directors
34th Piper Sandler Annual Healthcare Conference and RBC Capital Markets Healthcare Private Company Virtual Conference
34th Piper Sandler Annual Healthcare Conference and RBC Capital Markets Healthcare Private Company Virtual Conference
Scientific Data for Thryv’s Novel SGK1 inhibitors Presented at American Heart Association and San Antonio Breast Cancer Symposium
Scientific Data for Thryv’s Novel SGK1 inhibitors Presented at American Heart Association and San Antonio Breast Cancer Symposium
Dr. Debra Odink appointed to President and Dr. Shi Yin Foo joins our Board of Directors
Dr. Debra Odink appointed to President and Dr. Shi Yin Foo joins our Board of Directors
Expanding Pipeline Leads to Name Change - LQT Therapeutics Now Thryv Therapeutics
Expanding Pipeline Leads to Name Change - LQT Therapeutics Now Thryv Therapeutics
Douglas Wight Appointed as Vice President - Drug Development
Douglas Wight Appointed as Vice President - Drug Development
LQTT Collaboration with Leading Cancer Researcher
LQTT Collaboration with Leading Cancer Researcher
Award by the European Joint Program for Rare Diseases for SGK1 inhibition as a novel therapeutic approach in LQTS
Award by the European Joint Program for Rare Diseases for SGK1 inhibition as a novel therapeutic approach in LQTS
Dr. Eric Campeau appointed as LQTT Vice President – Translational Research
Dr. Eric Campeau appointed as LQTT Vice President – Translational Research

Isla Hutton

Long QT Type 3

We gain momentum everyday in our relentless pursuit of a treatment for Long QT Syndrome - In memory of Isla.

Isla Hutton
Isla Hutton
Isla Hutton
Isla Hutton
Isla Hutton
Isla Hutton
Isla Hutton
Isla Hutton
Isla Hutton
Isla Hutton
Isla Hutton

Together We Thryv

The enthusiasm of our investors is a reflection of breakthrough science, hard work and the dedication of our scientists, founders and collaborators.

Together we share a vision to transform the lives of people with life-threatening conditions.

Follow our journey